Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

14. März 2023 07:00 ET | Quelle: Sernova Corp.

Sernova Announces Upcoming Podium Presentation of iPSC and Cell Pouch™ Combination Treatment for Type One Diabetes at the 4th IPITA / HSCI / JDRF Summit

LONDON, Ontario, March 14, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, announced today that an abstract...
08. März 2023 07:00 ET | Quelle: Sernova Corp.

Sernova Announces Initial Islet Transplantation in First Two Patients Enrolled in Second Cohort of its U.S. Phase 1/2 Clinical Trial for Treatment of Type 1 Diabetes

Third patient now implanted with higher capacity, 10-chamber Cell PouchCompany anticipates first interim data from second cohort in Q4 2023 LONDON, Ontario, March 08, 2023 (GLOBE NEWSWIRE) --...
02. März 2023 07:00 ET | Quelle: Sernova Corp.

Sernova to Participate in Upcoming Roth and Oppenheimer Investor Conferences

LONDON, Ontario, March 02, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced it will be...
30. Januar 2023 07:30 ET | Quelle: Sernova Corp.

Sernova Announces Advancements with its Novel Cell Pouch System™ to Preserve Thyroid Function Following Total Thyroidectomy

Preclinical proof of concept study demonstrates that thyroid auto-transplantation into the Cell Pouch can restore thyroid hormone production following removal of the thyroid glandSernova has engaged...
10. Januar 2023 07:00 ET | Quelle: Sernova Corp.

Sernova and Evotec on Track to Initiate Clinical Testing of the First iPSC-Derived Islets in Cell Pouch as a Potential Functional Cure for Type 1 Diabetes

First iPSC-derived commercially viable off-the-shelf islet combination product is advancing towards regulatory filing in 2024 for anticipated clinical trial authorization to treat patients with Type...
06. Dezember 2022 07:00 ET | Quelle: Sernova Corp.

Sernova Corp. Announces CEO Succession Plan and Expanded Management Team

LONDON, Ontario, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Sernova Corp. (Sernova) (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, announced today that, as...
17. November 2022 07:30 ET | Quelle: Sernova Corp.

Sernova Announces First Two Patients Implanted with Cell Pouch™ in the Second Cohort of its US Phase 1/2 Clinical Trial for Type 1 Diabetes

Company’s recent recruitment strategy change has resulted in an unprecedented level of inquiries regarding potential study participationTransplantation of islets into the enhanced 10-channel Cell...
04. November 2022 07:30 ET | Quelle: Sernova Corp.

Sernova to Participate in the Stifel Healthcare Conference

LONDON, Ontario, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced it will be...
03. November 2022 07:30 ET | Quelle: Sernova Corp.

Sernova Receives Authorization to Enroll Second Patient Cohort of Phase 1/2 Trial with Cell Pouch System™ for Type 1 Diabetes

Sernova plans to begin enrollment of second cohort in the coming weeks and implant multiple patients with the enhanced capacity 10-channel Cell Pouch before the end of 2022Positive interim results...
28. September 2022 07:30 ET | Quelle: Sernova Corp.

Sernova to Participate in the Roth Inaugural Healthcare Opportunities Conference

LONDON, Ontario, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in regenerative cell therapeutics, today announced it...

Vorherige Seite

Nächste Seite